Structure-based discovery and development of metabotropic glutamate receptor 5 negative allosteric modulators

Area of Science:

• Neuroscience
• Pharmacology
• Biochemistry

Background:

• Metabotropic glutamate (mGlu) receptors are GPCRs crucial for CNS signaling.
• Dysregulation of mGlu receptors is implicated in various diseases, making them therapeutic targets.
• Targeting conserved orthosteric sites is challenging for subtype selectivity and drug-like properties.

Purpose of the Study:

• To explore structure-based drug design (SBDD) for developing selective mGlu receptor modulators.
• To detail the SBDD process for discovering the mGlu5 negative allosteric modulator HTL0014242.
• To investigate how receptor structure knowledge can elucidate activation mechanisms.

Main Methods:

• High-throughput screening and structure-based drug design (SBDD).
• Development of ligands targeting allosteric binding sites for enhanced selectivity.
• Utilizing structural insights for rational drug discovery.

Main Results:

• Discovery of HTL0014242, a negative allosteric modulator of the mGlu5 receptor.
• Demonstration of SBDD's efficacy in designing drug-like molecules with CNS penetration.
• Gained insights into mGlu receptor activation mechanisms through structural analysis.

Conclusions:

• Allosteric modulation provides a viable strategy for selective targeting of mGlu receptor subtypes.
• SBDD is a powerful approach for rational drug discovery, yielding compounds like HTL0014242.
• Structural knowledge of mGlu receptors is key to understanding their function and developing therapeutics.